### HANDBOOK OF CHEMICAL NEUROANATOMY

### VOLUME 11

### NEUROPEPTIDE RECEPTORS IN THE CNS

**Editors**:

A.Björklund, T.Hökfelt M.J. Kuhar

### HANDBOOK OF CHEMICAL NEUROANATOMY

Edited by A. Björklund and T. Hökfelt

Volume 11:

# NEUROPEPTIDE RECEPTORS IN THE CNS

Editors:

A. BJÖRKLUND

Department of Medical Cell Research, University of Lund, Lund, Sweden

T. HÖKFELT

Department of Histology and Neurobiology, Karolinska Institute, Stockholm, Sweden

M.J. KUHAR

Neuroscience Branch, NIDA Addiction Research Center, Baltimore, MD, U.S.A.



1992

### **ELSEVIER**

Amsterdam – London – New York – Tokyo

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the Publisher, Elsevier Science Publishers B.V., Copyright & Permissions Department, P.O. Box 521, 1000 AM Amsterdam, The Netherlands.

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of the rapid advances in the medical sciences, the Publisher recommends independent verification of diagnoses and drug dosages should be made.

Special regulations for readers in the USA. This publication has been registered with the Copyright Clearance Center, Inc. (CCC), Salem, Massachusetts, Information can be obtained from the CCC about conditions under which photocopies of parts of this publication may be made in the USA. All other copyright questions, including photocopying outside the USA, should be referred to the Publisher.

ISBN 0-444-89486-1 (volume) ISBN 0-444-90340-2 (series)

This book is printed on acid-free paper.

Published by: Elsevier Science Publishers B.V. P.O. Box 211 1000 AE Amsterdam The Netherlands

Library of Congress Cataloging-in-Publication Data

Neuropeptide receptors in the CNS / editors, A. Björklund, T. Hökfelt, M.J. Kuhar.

p. cm. -- (Handbook of chemical neuroanatomy; v. 11) Includes bibliographical references and index.

ISBN 0-444-89486-1 (alk. paper)

1. Neuropeptides--Receptors. 2. Neurochemistry. I. Björklund, Anders, 1945— . II. Hökfelt, Tomas. III. Kuhar, Michael J. IV. Series.

[DNLM: Brain--metabolism. 2. Neuropeptides--metabolism. W1 HA51J v. 11/ WL 300 N4938178]

QM451.H24 1983 vol. 11

[QP552.N39]

599'.048 s--dc20

[599'.0188]

DNLM/DLC

for Library of Congress

92-4424

CIP

### NEUROPEPTIDE RECEPTORS IN THE CNS

### List of contributors

#### A.M. ALLEN

University of Melbourne Department of Medicine Austin Hospital Heidelberg, Victoria 3084 Australia

#### T BARTFAI

Department of Biochemistry Arrhenius Laboratory University of Stockholm Stockholm Sweden

#### J. BATTEY

Laboratory of Neurochemistry National Institute of Neurological Disorders and Stroke National Institutes of Health Bethesda, MD 20892 USA

#### E. BRODIN

Department of Pharmacology Karolinska Institute Box 60400 S-104 01 Stockholm Sweden

#### P.M. CONN

Department of Pharmacology University of Iowa College of Medicine Bowen Science Building Iowa City, IA 52242-1109 U.S.A.

#### E.B. DE SOUZA

The Du Pont Merck Pharmaceutical Company Central Nervous System Disease Research Laboratory of Molecular and Cellular Experimental Station, E400/4352 P.O. Box 80400 Wilmington, DE 19880-0400 U.S.A.

#### PR HOF

Fishberg Research Center for Neurobiology and Department of Geriatrics and Adult Development Mount Sinai School of Medicine New York, NY 10029 U.S.A.

#### T. HÖKFELT

Department of Histology and Neurobiology Karolinska Institute Box 60400 S-104 01 Stockholm Sweden

#### D.M. JACOBOWITZ

Section of Histopharmacology Laboratory of Clinical Science National Institute of Mental Health Building 10, Room 3D-48 Bethesda, MD 20892 USA

#### L. JENNES

Department of Anatomy Wright State University School of Medicine 252 Biosciences Building Dayton, OH 45435 U.S.A.

#### C. KÖHLER

Department of Neurochemistry **ASTRA Pharmaceuticals** Södertälie Sweden

#### S. KRANTIC

Biology ENS de Lyon 46 Aveneu d'Italie 69364 Lyon, Cedex 07 France

#### P.I. MAGISTRETTI

Institut de Physiologie Faculté de Médicine Université de Lausanne 7 rue du Bugnon CH-1005 Lausanne Switzerland

#### J.-C. MARTEL

Douglas Hospital Research Center and Departments of Psychiatry, and Pharmacology and Therapeutics Faculty of Medicine McGill University 6875 LaSalle Boulevard Verdun, Quebec Canada H4H 1R3

#### J.-L. MARTIN

Institut de Physiologie Faculté de Médecine Université de Lausanne 7 rue du Bugnon CH-1005 Lausanne Switzerland

#### T. MELANDER

Department of Histology and Neurobiology Karolinska Institute Box 60400 S-104 01 Stockholm Sweden

#### F.A.O. MENDELSOHN

Department of Medicine Austin Hospital University of Melbourne Heidelberg, Victoria 3084 Australia

#### T.W. MOODY

Department of Biochemistry and Molecular Biology The George Washington University School of Medicine and Health Sciences 2300 Eye Street NW Washington, DC 20037 U.S.A.

#### S NILSSON

Department of Histology and Neurobiology Karolinska Institute Box 60400 S-104 01 Stockholm Sweden

#### IM PALACIOS

Preclinical Research Sandoz Ltd CH-4002 Basel Switzerland

#### G. PAXINOS

School of Psychology University of New South Wales Kinsington, NSW 2033 Australia

#### R. OUIRION

Douglas Hospital Research Center and Departments of Psychiatry, and Pharmacology and Therapeutics Faculty of Medicine McGill University 6875 LaSalle Boulevard Verdun, Quebec Canada H4H 1R3

#### J.M. SAAVEDRA

Section of Pharmacology Laboratory of Clinical Science National Institute of Mental Health 9000 Rockville Pike, Building 10, Room 2D-45 Bethesda, MD 20892 U.S.A.

#### G. SKOFITSCH

Department of Zoology Karl-Franzens-Universität Universitätsplatz 2 A-8010 Graz Austria

#### K.F. SONG

University of Melbourne Department of Medicine Austin Hospital Heidelberg, Victoria 3084 Australia

#### E. THEODORSSON

Department of Clinical Chemistry Karolinska Hospital Stockholm Sweden

#### E. TRIBOLLET

Department of Physiology University Medical Center 1 rue Michel Servet 1211 Geneva 4 Switzerland

#### K. TSUTSUMI

Section of Pharmacology Laboratory of Clinical Science National Institute of Mental Health 9000 Rockville Pike, Building 10, Room 2D-45 Bethesda, MD 20892 U.S.A.

#### G. UHL

Laboratory of Molecular Neurobiology ARC/NIDA and Departments of Neurology and Neuroscience Johns Hopkins School of Medicine Box 5180 Baltimore, MD 21224 U.S.A.

#### E. WADA

Laboratory of Neurochemistry National Institute of Neurological Disorders and Stroke National Institutes of Health Bethesda, MD 20892 U.S.A.

#### S. ZORAD

Section of Pharmacology Laboratory of Clinical Science National Institute of Mental Health 9000 Rockville Pike, Building 10, Room 2D-45 Bethesda, MD 20892 U.S.A.

### **Preface**

This volume is the third in this series on neurotransmitter receptors. The first two dealt with receptors for classical neurotransmitters and with receptors for other neuropeptides. This volume extends and updates the information on peptide receptors, and it complements chapters on some of the peptides themselves in earlier volumes.

The peptides, from angiotensin to vasoactive intestinal peptide, are striking in the diversity of their origins, discoveries and actions. Atrial natriuretic peptide is produced by the cardiac atria, bombesin by the frog skin, CRH by the hypothalmus, and galanin by the small intestine; they are also found in many other organs including the brain. Angiotensin has the central action of stimulating drinking behavior but also has peripheral actions on smooth muscle and kidney. CRH acts at the pituitary but has more central behavioral effects as well. Some of these peptides such as neuropeptide Y are very abundant in brain while others are not. The fact that the brain displays such variety is both staggering and challenging.

This apparent diversity multiplies when it is realized that there are entire families of closely related peptides in many cases, and that each peptide may act at a variety of receptor subtypes. For example, calcitonin and calcitonin gene-related peptide are processing variants of the same gene, and somatostatin receptors are target sites for a family of peptides.

Regarding multiple or subtypes of receptors, it seems certain that more is to come in the future. This volume is basically a compilation of 'high affinity' receptors for agonists since we are using the neuropeptides themselves as ligands. Perhaps significant numbers of low affinity receptors exist that are not easily recognized under the binding and washing conditions employed. As peptide receptors are further understood and as antagonists are developed, additional families or subtypes of receptors may be identified and mapped with resultant increases in our ideas about their functions.

Mapping receptors helps us understand the neuronal sites of action and hence the physiological effects of the peptides. It also provides us with an additional perspective by which we view the biochemical organization of the brain. It is our hope that these organized chapters help us utilize and deal with the abundant knowledge on this topic as well as to incorporate this knowledge for future advances.

Finally we acknowledge our good fortune in having an excellent group of authors, each expert in their respective areas. They have addressed the diversity of neuropeptides and their receptors and have produced excellent state-of-the-art chapters. We thank them for their patient and thorough efforts in producing this fine volume. Also, warm thanks go to our friends at Elsevier who with never failing enthusiasm and great professional competence have made this volume possible.

Lund, Stockholm and Baltimore in May 1992

ANDERS BJÖRKLUND

TOMAS HÖKFELT

MICHAEL J. KUHAR

### Contents

## I. LOCALIZATION OF ANGIOTENSIN RECEPTOR BINDING SITES IN THE RAT BRAIN – A.M. ALLEN, G. PAXINOS, K.F. SONG AND F.A.O. MENDELSOHN

1.	Introduction	1		
2.	Localization of ANG receptor binding sites in rat brain			
	2.1. In vitro autoradiography	4		
3.	Distribution of <sup>125</sup> I-[SAR <sup>1</sup> ,ILE <sup>8</sup> ]ANG II binding in rat brain	5		
	3.1. Non-specific binding	5		
	3.2. Distribution of specific ANG receptor binding in rat brain	4		
	3.2.1. Circumventricular organs	6		
	3.2.2. Cerebral cortex	6		
	3.2.3. Olfactory system	10		
	3.2.4. Septum and hypothalamus	13		
	3.2.5. Amygdala and bed nucleus of the stria terminalis	14		
	3.2.6. Thalamus	14		
	3.2.7. Basal ganglia	15		
	3.2.8. The visual system	15		
	3.2.9. Hippocampus	15		
	3.2.10. Raphe nuclei	15		
	3.2.11. Central gray	15		
	3.2.12. Brainstem nuclei associated with cardiovascular, respirato-			
	ry and other autonomic functions	16		
	3.2.13. The auditory system	16		
	3.2.14. The somatosensory system	16		
	3.2.15. The pre-cerebellar nuclei	16		
	3.2.16. Cervical spinal cord	16		
4.	Correlation with previous in vitro autoradiographic studies	17		
	4.1. Preoptic structures	17		
	4.2. Magnocellular neurosecretory nuclei	17		
	4.3. Amygdala	18		
	4.4. Striatum	18		
	4.5. Midbrain	18		
	4.6. Pons	18		
_	4.7. Medulla	18		
5.	Subtypes of ANG receptor binding sites	20		
6.	Distribution of ANG immunoreactivity in rat brain	20		
	6.1. Correlation between the distribution of ANG-immunoreactive			
_	terminal fields and ANG receptor binding sites	20		
	Neuronal release of ANG	24		
	Distribution of ANG II-responsive neurones	24		
9.	Correlation between the distribution of ANG receptor binding sites and			
	regions of ANG II action	25		

		9.1.	Cardiovascular regulation	25
		9.2.	Drinking	25
		9.3.	Neuroendocrine actions	26
		9.4.	Other possible actions	26
			9.4.1. Somatosensory function	27
			9.4.2. Viscerosensory function	27
			9.4.3. Special sensation	27
			9.4.4. Memory and learning	27
	10.	Conc	clusion	28
	11.	Abbr	reviations	28
	12.	Refe	rences	32
			ZATION OF ATRIAL NATRIURETIC PEPTIDE B AND C	
			ORS IN RAT BRAIN – J.M. SAAVEDRA, S. ZORAD AND	
k	(. T	SUTS	SUMI	
	1.	Intro	duction	39
		1.1.	The atrial natriuretic peptide	39
			Atrial natriuretic peptide in the brain	39
		1.3.	Central effects of atrial natriuretic peptide	39
		1.4.	Atrial natriuretic peptide receptors in brain	39
		1.5.	Atrial natriuretic peptide receptors are heterogeneous	40
	2.	Mate	erials and methods	41
		2.1.	Animals	41
		2.2.	Preparation of brain sections	41
ď		2.3.	Atrial natriuretic peptide receptor binding	41
		2.4.	Quantitative autoradiography	42
		2.5.	Determination of ligand metabolism	42
		2.6.	Materials	42
	3.	Resu	ılts	42
		3.1.	Determination of ligand stability during incubation procedures	42
		3.2.	Distribution of ANP receptors in the rat brain and pituitary	43
		3.3.	Localization and quantification of c-ANP receptors in the rat	
			brain	47
	4.	Disc	ussion	48
		4.1.	The use of quantitative autoradiography for the analysis of pep-	
			tide receptors	48
		4.2.	Quantitative autoradiography of ANP receptors	48
		4.3.	Distribution of brain and pituitary ANP receptors. Comparison	
		· marketing	between different studies, and interspecies differences	49
		4.4.	Comparison of ANP receptor distribution and ANP localization	.,
			in brain	49
		4.5.	Physiological correlates of brain ANP receptors	51
	5		clusions	51
			rences	52

III.	BOMBESIN/GRP	RECEPTORS - T.W	MOODY, E.	WADA AND
	I BATTEY			

	1.	Introduction	55
	2.4	1.1. Structure of peptides	55
	2.	GRP and NMB receptors	57
		In vitro autoradiography	60
		Binding to rat brain sections	61
		In situ hybridization	63
		Localization of GRP receptors	64
		Localization of NMB receptors	90
		Receptor peptide mismatch	90
	9.	Summary	91
	10.	Acknowledgements	92
	11.	References	92
IV.	CA	LCITONIN- AND CALCITONIN GENE-RELATED PEPTIDE:	
		CEPTOR BINDING SITES IN THE CENTRAL NERVOUS SYSTEM	
	-G	. SKOFITSCH AND D.M. JACOBOWITZ	
	9	Introduction	97
			100
	۷.	Receptor autoradiography of rat brain 2.1. Telencephalon/rhinencephalon	115
		2.2. Diencephalon	120
		2.3. Mesencephalon	125
		2.4. Pons	125
		2.5. Cerebellum	126
		2.6. Myelencephalon	126
		2.7. Spinal cord	127
		2.8. Pituitary	127
	3.	Biochemistry and physiology	128
		3.1. CT/CGRP precursor types	128
		3.2. CT/CGRP receptor types	128
		3.3. Functional significance	130
		3.4. Receptor continuity	133
		Summary	134
		Acknowledgements	134
	6.		134
	7.	References	139
V.		RTICOTROPIN-RELEASING HORMONE RECEPTORS –	
	E.B	. DE SOUZA	
	1.	Introduction	145
	2.	General characteristics	148
		2.1. Kinetics and pharmacology	148
			xiii

		2.2. 2.3.	Biochemical properties Second messengers	149 149
	3		radiographic localization studies	150
	٥.	3.1.	Methods	150
		2.1.	3.1.1. Choice of radioligand	150
			3.1.2. Tissue preparation	150
			3.1.3. Receptor labeling in slide-mounted brain sections	151
			3.1.4. Autoradiography	151
			3.1.5. Data analysis	151
		3.2.	Distribution in the pituitary gland	151
		3.3.	Distribution in the central nervous system	154
			3.3.1. Rat CNS	154
			3.3.1.1. Olfactory system	154
			3.3.1.2. Cerebral cortex	154
			3.3.1.3. Limbic system	159
			3.3.1.4. Thalamus-hypothalamus	162
			3.3.1.5. Brainstem	163
			3.3.1.6. Cerebellum	163
			3.3.1.7. Spinal cord	164
			3.3.2. Primate brain	165
		3.4.	Distribution in peripheral tissues	
			3.4.1. Spleen	166
		~	3.4.2. Peripheral sympathetic nervous system	167
	4.	Corr	elation of CRH receptors with CRH-like immunoreactivity	
			ets of CRH on cerebral metabolism: 2-deoxyglucose studies	168
			geny of CRH receptors	170
			ets of aging on CRH receptors	170
	8.		of CRH in central nervous system disorders	173
		8.1.	Neuropsychiatric disorders	173
			8.1.1. Affective disorders	173
		0.3	8.1.2. Anxiety-related disorders	174
		8.2.	Neurodegenerative diseases	174
			8.2.1. Alzheimer's disease	174
	0	C	8.2.2. Huntington's disease	176
			mary and conclusions	177
			nowledgements reviations	177
			rences	177
	12.	Reie	rences	179
VI.	SYS	STEM	ANIN BINDING SITES IN THE RAT CENTRAL NERVOUS I – TOR MELANDER, C. KÖHLER, S. NILSSON, G. FISONE, FAI AND T. HÖKFELT	
	1	Inter-	duction	
	1.		Dischanged share stanistics of CAL hindiansis	187
		1.1.	Biochemical characteristics of GAL binding sites	187
	2	1.2.	Biological effects of GAL	188
	2.	2.1.	Productions and methods	189
		4.1.	Radioligand	189

		2.2. Autoradiography	189
	3.	Distribution of <sup>125</sup> I-GAL binding sites	190
		3.1. Telencephalon	190
		3.1.1. Hippocampal formation	190
		3.2. Diencephalon	209
		3.2.1. Thalamus	209
		3.2.2. Hypothalamus	209
		3.3. Mesencephalon	210
		3.4. Rhombencephalon	210
		3.5. Spinal cord	211
	4.	Correlation to immunocytochemical results	211
		Summary	212
		Acknowledgements	212
		Abbreviations	212
		References	215
VII.		DNADOTROPIN-RELEASING HORMONE RECEPTORS IN RAT	
	BR	RAIN – L. JENNES AND P.M. CONN	
	1.	Introduction	223
		1.1. Function of GnRH	223
	2	1.2. Structure of GnRH and its analogs	224
	2.	Methods	224
		2.1. Iodination of GnRH analogs	224
		2.2. 'In vitro' autoradiography	225
		2.3. 'In vivo' autoradiography	225
		2.4. Radioreceptor assay	225
	2	2.5. Photoaffinity labeling	226
		Distribution of GnRH binding sites in the central nervous system	226
		3.1. 'In vitro' autoradiography	226
		3.2. Development of GnRH binding sites	227
	4	3.3. 'In vivo' autoradiography	227
	4.	Characterization of GnRH binding sites in the hippocampus	233
		4.1. 'In vitro' autoradiography	233
		4.2. Radioreceptor assay	233
		4.3. Photoaffinity labeling	235
	-	4.4. Comparison of hippocampal and pituitary GnRH binding sites	235
	5.	Effects of GnRH in the hippocampus	237
		5.1. Electrophysiology	237
		5.2. Fos expression	238
	~	5.3. Effects of gonadal steroids on hippocampal GnRH binding sites	239
		Discussion	239
		Acknowledgement	240
		Abbreviations	240
	9.	References	243

## VIII. BRAIN NEUROPEPTIDE Y RECEPTORS: DISTRIBUTION AND POSSIBLE RELEVANCE TO FUNCTION – R. QUIRION AND J.-C. MARTEL

	1.	Introduction	247
	2.	Discovery of NPY	247
	3.	Distribution of brain NPY-like immunoreactivity	248
		3.1. NPY projection pathways	250
		3.2. Co-localization with other transmitters	251
	4.	Biological effects of NPY in the CNS	252
	5.	Brain NPY receptors	254
		5.1. Methods	254
		5.2. Ligand selectivity profile	257
		5.3. Autoradiographic distribution	257
		5.3.1. Rhinencephalon	257
		5.3.2. Telencephalon	269
		5.3.3. Diencephalon	270
		5.3.4. Mesencephalon	271
		5.3.5. Metencephalon	272
		5.3.6. Myelencephalon	272
	6.	Brain NPY receptors in other species	273
		Brain NPY receptor subtypes	273
		Conclusion	276
		Acknowledgements	276
		Abbreviations	276
	11.	References	279
IX.		SOPRESSIN AND OXYTOCIN RECEPTORS IN THE RAT BRAIN . TRIBOLLET	
	ï	Introduction	289
		Procedures for localizing AVP and OT receptors	290
	4.	2.1. Radiolabeled ligands	290
		2.2. Labeling of AVP receptors	290
		2.3. Labeling of OT receptors	292
	3.	Distribution of AVP and OT receptors	293
		3.1. Distribution of AVP receptors	294
		3.1.1. Olfactory system	294
		3.1.2. Limbic system	294
		3.1.3. Hypothalamus	294
		3.1.4. Thalamus	304
		3.1.5. Brainstem and spinal cord	304
		3.1.6. Choroid plexus and circumventricular organs	304
		3.2. Distribution of OT receptors	304
		3.2.1. Olfactory system	304
		3.2.2. Basal ganglia	304
		3.2.3. Limbic system	305
		3.2.4. Thalamus	305

		3.2.5. Hypothalamus	305
	4	3.2.6. Brainstem and spinal cord Pharmacological characterization of brain AVP binding sites as V <sub>1</sub> type	305
	415	receptors	306
	5.	AVP and OT receptors during development	306
		Effects of gonadal steroids on AVP and OT receptor number	312
		Concluding remarks	314
	8.	Acknowledgements	315
		Abbreviations	315
	10.	References	316
Χ.	G. U	MATOSTATIN RECEPTORS – S. KRANTIC, R. QUIRION AND JHL	
	1.	Introduction	321
	2.	Somatostatin binding sites in rat brain	323
		2.1. Methodologic considerations	323
		2.2. Biochemical studies	323
		2.3. Autoradiographic studies	324
		Heterogeneity of somatostatin binding sites in rat brain	329
		Somatostatin receptors in human brain	333
		Match between somatostatinergic neurons and receptors in rat CNS	335
		Functional relevance	338
		Conclusions	340
		Abbreviations	340
	9.	References	342
XI.	VAS	SOACTIVE INTESTINAL PEPTIDE (VIP) RECEPTORS –	
		MAGISTRETTI, JL. MARTIN, P.R. HOF AND J.M. PALACIOS	
	1.	Introduction	347
		Preparation and characterization of [125I-Monoiodo Tyr <sup>10</sup> , MetO <sup>17</sup> ]-	211
		vasoactive intestinal peptide	347
	3.	Autoradiographic procedure	350
		3.1. Stability of M-[ <sup>125</sup> I]VIP in the incubation medium	351
	4.	Pharmacological characteristics of M-[125I]VIP binding sites in rat brain	
		sections	352
		4.1. Kinetic analysis	352
	-	4.2. Pharmacological specificity of M-[125I]VIP binding	353
	٥.	Distribution of VIP binding sites	353
		5.1. Rodent brain (rat, mouse and guinea pig)	354
		5.2 Other species 5.2.1. Teleostean brain	363
		5.2.2. Anuran brain	364
		5.2.3. Reptilian brain	366
		5.2.4. Avian brain	367
		5.2.5. Cat brain	368
			371
		of some of the source of the s	xvii

		5.2.6. Primate brain	371
	6.	Comments and discussion	373
		6.1. Phylogeny	373
		6.2. Matching with VIP immunoreactivity	375
		6.3. Functional aspects	386
	7.	Acknowledgements	389
		Abbreviations	389
	9.	References	397
SU	BJE	CT INDEX	397

CHAPTER I

## Localization of angiotensin receptor binding sites in the rat brain

A.M. ALLEN, G. PAXINOS, K.F. SONG AND F.A.O. MENDELSOHN

#### 1. INTRODUCTION

Angiotensin (Ang) is a circulating hormone with potent actions on vascular smooth muscle, renal function and the adrenal gland (see Peach 1977). Ang also has central actions including stimulation of drinking behaviour, regulation of the central control of the autonomic nervous system, and stimulation of the release of both anterior and posterior pituitary hormones (see Phillips 1987). Overall these actions relate to the maintenance of fluid and electrolyte homeostasis and cardiovascular function. However, some more diverse actions, including effects on learning and memory (Koller et al. 1975; Baranowska et al. 1983), have been observed following manipulation of the central reninangiotensin system.

Initially the central actions of Ang were thought to be mediated solely by circulating Ang II acting at the circumventricular organs. These specialized brain regions are accessible to circulating Ang because they have a deficient blood—brain barrier (Simpson 1980; McKinley et al. 1990). Several of the circumventricular organs, including the subfornical organ, vascular organ of the lamina terminalis (OVLT), median eminence and area postrema, are rich in Ang receptor binding sites (Van Houten et al. 1980; Mendelsohn et al. 1984), and electrophysiological studies show that neurons in the subfornical organ are excited by Ang II administered intravenously (Ishibashi et al. 1985; Ferguson and Renaud 1986).

The discovery that all components of the renin-angiotensin system occur in brain (Yang and Neff 1972; Hirose et al. 1978; Lewicki et al. 1978; Ganten et al. 1983) led to the proposal of an endogenous brain renin-angiotensin system. Supporting this, Anglike immunoreactive neurons, Ang receptor binding sites and Ang responsive neurons have been demonstrated at sites within the blood–brain barrier (see Lind 1987). In addition, microinjection of Ang II into several restricted regions behind the blood–brain produces pressor, dipsogenic, cardiovascular and neuroendocrine actions (see Phillips 1987).

The concept of an endogenous brain angiotensin system was not readily accepted. The isolation of Ang II from brain proved difficult, presumably due to the rapid degradation of this peptide (Harding et al. 1986; Abhold and Harding 1987) and its low concentration. However, several groups have isolated material from brain which behaves like synthetic Ang II in radioimmunoassay and radioreceptor assay (Ganten et al. 1983; Simon-

Handbook of Chemical Neuroanatomy, Vol. 11: Neuropeptide Receptors in the CNS. A. Björklund, T. Hökfelt and M.J. Kuhar, editors.